Peptide Therapy Development Services
Welcome to Alfa Cytology's peptide therapeutics development services tailored specifically for cancer treatment. At Alfa Cytology, we specialize in leveraging the unique properties of peptides to create targeted therapies designed to combat cancer with precision and efficacy. Our comprehensive suite of services encompasses peptide design, synthesis, and conjugation, paving the way for innovative treatments that hold promise in the fight against cancer.
Overview of Peptide Therapy
Peptide therapeutics development services at Alfa Cytology represent a groundbreaking approach to cancer treatment, harnessing the inherent specificity and versatility of peptides to target tumor cells with unparalleled precision. Peptides offer a promising platform for developing therapeutics that selectively disrupt key signaling pathways involved in cancer progression, offering new avenues for personalized cancer therapy. From peptide design and synthesis to drug conjugation and formulation, our integrated services cover every aspect of peptide-based drug development, with a singular focus on addressing the unique challenges posed by cancer.
Fig.1 Structure of peptide-drug conjugates. (Vadevoo, S. M. P., et al., 2023)
Peptides have lower affinity and shorter half-life in vivo compared to antibodies. Conversely, peptides exhibit higher efficiency in tissue penetration and cellular internalization compared to antibodies. Regardless of the advantages and disadvantages of peptides, they have been used as tumor-localizing ligands for delivery of carriers (e.g., nanoparticles, extracellular vesicles, and cells) and cargoes (e.g., cytotoxic peptides and radioisotopes) to tumors. In addition, tumor-localizing peptides can be linked to carriers such as small molecule drugs or chemotherapeutic agents via linkers to synthesize peptide-drug conjugates. In addition, peptides can selectively bind to cell surface receptors and proteins (e.g., immune checkpoints, receptor kinases, and hormone receptors), thereby blocking their biological activity or acting as hormone analogs. In addition, peptides internalized into cells bind to intracellular proteins and interfere with protein interactions.
Fig.2 Types of peptides, carriers and payloads. (Vadevoo, S. M. P., et al., 2023)
Our Services
RNA vaccines offer several advantages, including the simultaneous encoding of multiple antigens and full-length tumor antigens. They can be produced quickly, flexibly, and efficiently, making them ideal for personalized neoantigen vaccine preparation. Moreover, RNA vaccines have a high safety profile, as they do not integrate into the host genome. Followings are the services we offer during the RNA cancer vaccine development.
Peptide Design and Synthesis
- Customized design of peptides targeting specific cancer biomarkers or signaling pathways.
- Synthesis of high-purity peptides using advanced techniques and methodologies tailored for cancer therapy.
Peptide Drug Conjugates Development
- Conjugation of peptides with cytotoxic agents or targeting ligands to enhance anti-cancer efficacy.
- Optimization of conjugation strategies to ensure stability, specificity, and selective delivery to tumor cells.
Advantages of Our Service
Targeted Therapy
Peptides engineered to selectively target cancer cells while sparing healthy tissues, minimizing off-target effects.
Personalized Treatment
Tailored peptide designs and formulations to address the unique molecular characteristics of each patient's cancer.
Enhanced Efficacy
Peptide therapeutics with potent anti-cancer activity, capable of disrupting key signaling pathways essential for tumor growth and survival.
Safety Profile
Peptides with favorable safety profiles and reduced systemic toxicity, ensuring greater tolerability and patient well-being.
Choose Alfa Cytology for peptide therapeutics development services in the fight against cancer, and join us in advancing the forefront of personalized cancer therapy. Contact us freely, and get started with our innovative services.
Reference
- Vadevoo, S. M. P., et al.; (2023). Peptides as multifunctional players in cancer therapy. Experimental & Molecular Medicine, 55(6), 1099-1109.
For research use only.
Related Services
